ENDOCRINE ASPECTS OF AMIODARONE THERAPY IN CLINICAL PRACTICE (FOLLOW-UP AND TREATMENT ALGORITHM FOR PATIENTS WITH THYROID DYSFUNCTION)
Abstract
This review discusses the effects of amiodarone on thyroid function and summarises the results of international studies and the evidence obtained by the researchers from the A.L. Myasnikov Research Institute of Clinical Cardiology and Endocrinology Research Centre. The guidelines on thyroid dysfunction diagnostics and therapy, as well as the follow-up of amiodarone-treated patients, are presented.
About the Authors
N. Yu. Sviridenko
Endocrinology Research Centre, Moscow, Russia
Russian Federation
Russian Federation
N. M. Platonova
Endocrinology Research Centre, Moscow, Russia
Russian Federation
Russian Federation
N. V. Molashenko
Endocrinology Research Centre, Moscow, Russia
Russian Federation
Russian Federation
S. P. Golitsyn
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex Moscow, Russia
Russian Federation
Russian Federation
S. A. Bakalov
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex Moscow, Russia
Russian Federation
Russian Federation
S. E. Serdyuk
State Research Centre for Preventive Medicine, Moscow, Russia
Russian Federation
Russian Federation
References
1. Golitsyn SP. Amiodaron: decades of administration Ter Arkh. 2011;83 (8):25–33. Russian (Голицын С.П. Амиодарон десятилетия спустя. Тер.арх. 2011;83 (8):25–33).
2. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual date from 6500 patients in randomized trials. Lancet 1997; 350: 1417–1424
3. Dedov II, Mel’nichenko GA, Sviridenko NIu, et al. Diagnostics, treatment, and prevention of iatrogenic iodine-induced thyroid gland diseases. Vestn Ross Akad Med Nauk. 2006; 1: 15–22. Russian. (Дедов И.И., Мельниченко Г.А., Свириденко Н.Ю. и др. Диагностика, профилактика и лечение ятрогенных йодиндуцированных заболеваний щитовидной железы. Вестник РАМН 2006; 1: 15–22).
4. Mel’nichenko GA, Sviridenko NIu, Molashenko NV, et al. Amiodarone-induced thyroid dysfunction (pathogenesis, diagnosis, treatment). Ter Arkh. 2003; 75 (8): 92–96. Russian (Мельниченко Г.А., Свириденко Н.Ю., Молашенко Н.В., и др., Индуцированная амиодароном дисфункция щитовидной железы. Тер. Архив. 2003; 8: 92–96).
5. Rao R.H., McCready V.R. Iodine kinetic studies during Amiodarone treatment.J. Clin Endocrinol Metab. 1986; 62 (3): 563–567.
6. Vitale M, Di Matola T, D’Ascoli F, et al. Iodine excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress.J. Endocrinol. 2000; 141 (2): 598–605.
7. Martino E., Bartalena L., Bogazzi F., Braverman L.E. The effects of amiodarone on the Thyroid Endokrine Reviews 2001; 22 (2): 240–254.
8. Platonova N., Molashenko N., Sviridenko N. Management of patients with amiodaroninduced thyrotoxicosis and euthyroid hyperthyroxinemia. The Thyroid and cardiovascular risk Stuttgart; New York, 2004; 96–97.
9. Singh, B.N. The historical development, cellular electrophysiology and pharmacology of amiodarone In: Singh B.N., Vencatesh N., Kannan R. Progress in cardiovascular diseases 1989; 31 (4): 249–280.
10. D.I. Matola Т., D.’Ascoli F., Fenzi G. et al. Amiodarone induces cytochrome С release and apoptosis through an iodine-independent mechanism. J Clin Endocrinol Metab. 2000; 85 (11): 4323–4330.
11. Sviridenko N., Molashenko N., Platonova N. Lipid disorders in amiodarone-treated patients with subclinical hypothyroidism In: The Thyroid and cardiovascular risk. Stuttgart; New York, 2004; 99–100.
12. Ursella S., Testa A., Mazzone M. et al. Amiodarone-induced thyroid dysfunction in clinical practice. Eur Rev Med Pharmacol Sci 2005; 10: 269–278.
13. Bogazzi F., Bartalena L., Gasperi M. The various effects of amiodarone on thyroid function. Thyroid 2001; 11 (5): 511–519.
14. Serdiuk SE, Bakalov SA, Golitsyn SP, et al. Incidence and predictors of thyroid dysfunction caused by long-term intake of amiodaron. Ter Arkh. 2005; 77 (10): 33–39. Russian. (Сердюк С.Е., Бакалов С.А., Голицын С.П. и др. Частота возникновения и предикторы развития амиодарон-ассоциированных дисфункций щитовидной железы. Тер. арх. 2005; (10): 33–38).
15. Sviridenko N.Iu. Functional autonomy at an endemic goiter. Probl. Endocrinol. 2005; 1: 40–42. Russian (Свириденко Н.Ю. Функциональная автономия при эндемическом зобе. Пробл. эндокринол. 2005; 1: 40–42).
16. Molashenko NV, Sviridenko NIu, Platonova NM, et al. The specific features of thyrotoxicosis and euthyroid hyperthyroxinemia developed due to the use of cordarone. Clin Med (Mosk). 2004; 82 (12): 35–9. Russian (Молашенко Н.В., Свириденко Н.Ю., Платонова Н.М. и др. Особенности тиреотоксикоза и тирeоидной гипертироксeмии при применении кордарона. Клин. Медицина 2004; 82 (12): 35–9).
17. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med., 2001; 344 (7): 501–509.
18. Igonin V. A., Proskurin V. M., Serebrennikov V. N., et al. Amiodarone–induced thyrotoxicosis: difficulties of diagnostics and treatment. Clin. Thyreoid. 2004; 2 (4): 53–55. Russian (Игонин В.А., Проскурин В.М., Серебренников В.Н. и др. Амиодарон- ассоциированный тиреотоксикоз: сложности диагностики и лечения. Клин. тиреои- дол. 2004; 2 (4): 53–55).
19. Serdiuk SE, Bakalov SA, Golitsyn SP. et al. Thyroid dysfunction in long-term amiodarone administration. Correlation of the antiarrhythmic activity of amiodarone with its effect on thyroid function. Kardiolog. 2005; 45 (1): 22–27. Russian. (Сердюк С. Е., Бакалов С. А., Голицин С. П. и др. Дисфункция щитовидной железы на фоне длительного приема амиодарона. Связь антиаритмической эффективности амиодарона с действием препарата на функцию щитовидной железы. Кардиология 2005; 45 (1): 22–27).
20. Eaton S.E., Euinton H.A., Newman C.M. et al. Clinical experience of amiodaroneinduced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin. Endocrinol. (Oxf). 2002; 56 (1): 33–38.
21. Sviridenko NIu, Molashenko NV, Platonova NM, et al. Functional condition of a thyroid gland at the patients accepting амиодарон. Methods of correction of thyroid dysfunction. Clin Thyreoid. 2004; 2 (4): 19–26. Russian (Свириденко Н.Ю., Молашенко Н.В., Платонова Н.М. и др. Функциональное состояние щитовидной железы у пациентов, принимающих амиодарон. Методы коррекции тиреоидной дисфункции. Клин. тире- оидол. 2004; 2 (4): 19–26).
22. Erdogan M. Treatment of amiodarone-induced thyrotoxicosis In: The thyroid and cardiovascular risk/Merck European thyroid symposium, Berlin. 2004; 85–90.
23. Serdiuk SE, Bakalov SA, Golitsyn SP, et al. Lipid blood spectrum in patients with amiodarone associated hypothyroidism. Effect of replacement therapy with L-thyroxine. Kardiolog. 2005; 45 (2): 11–14. Russian. (Сердюк С.Е., Бакалов С.А., Голицин С.П. и др. Состояние липидного спектра крови у больных гипотиреозом, вызванным длительным применением амиодарона. Влияние заместительной терапии L-тироксином. Кардиология 2005; 2: 11–14).
Review
For citations:
Sviridenko N.Yu., Platonova N.M., Molashenko N.V., Golitsyn S.P., Bakalov S.A., Serdyuk S.E. ENDOCRINE ASPECTS OF AMIODARONE THERAPY IN CLINICAL PRACTICE (FOLLOW-UP AND TREATMENT ALGORITHM FOR PATIENTS WITH THYROID DYSFUNCTION). Russian Journal of Cardiology. 2012;(2):63-71. (In Russ.)
Views:
752
Email this article 